NASDAQ:CPIX Cumberland Pharmaceuticals (CPIX) Stock Price, News & Analysis $7.80 +0.21 (+2.70%) As of 10:27 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC Filings About Cumberland Pharmaceuticals Stock (NASDAQ:CPIX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CPIX alerts:Sign Up Key Stats Today's Range$7.50▼$7.7550-Day Range$6.29▼$8.9752-Week Range$1.85▼$9.28Volume10,092 shsAverage Volume421,372 shsMarket Capitalization$116.77 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, acquisition and commercialization of prescription products for hospital care, gastroenterology and other targeted therapeutic areas. The company’s business model emphasizes branded medicines that address specific clinical needs and are marketed primarily in the United States. Its product portfolio has included Acetadote (acetylcysteine injection), used in the treatment of acetaminophen poisoning; Caldolor (ibuprofen injection), an intravenous nonsteroidal anti-inflammatory drug for pain and fever; and Kristalose (lactulose), a prescription treatment for constipation. Cumberland has also marketed products such as Vaprisol, used to manage certain cases of low blood sodium, and Omeclamox-Pak, a treatment for Helicobacter pylori infection and associated duodenal ulcers. Founded in 1999, Cumberland has expanded its portfolio through internal development, licensing agreements and acquisitions. The company is led by A.J. Kazimi, its co-founder, chairman and chief executive officer. Cumberland’s products are distributed through its commercial operations and selected business partners, with its primary commercial focus on the U.S. healthcare market.AI Generated. May Contain Errors. Read More Cumberland Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks16th Percentile Overall ScoreCPIX MarketRank™: Cumberland Pharmaceuticals scored higher than 16% of companies evaluated by MarketBeat, and ranked 834th out of 898 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingCumberland Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageCumberland Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Cumberland Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Cumberland Pharmaceuticals is -10.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cumberland Pharmaceuticals is -10.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCumberland Pharmaceuticals has a P/B Ratio of 4.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cumberland Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.16% of the float of Cumberland Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCumberland Pharmaceuticals has a short interest ratio ("days to cover") of 3.03, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cumberland Pharmaceuticals has recently decreased by 15.80%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCumberland Pharmaceuticals does not currently pay a dividend.Dividend GrowthCumberland Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.25 News SentimentCumberland Pharmaceuticals has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cumberland Pharmaceuticals this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added Cumberland Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cumberland Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders42.07% of the stock of Cumberland Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions15.51% of the stock of Cumberland Pharmaceuticals is held by institutions.Read more about Cumberland Pharmaceuticals' insider trading history. Receive CPIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cumberland Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CPIX Stock News HeadlinesCumberland Pharmaceuticals (NASDAQ:CPIX) Shares Pass Above Two Hundred Day Moving Average - Time to Sell?September 16, 2026 | americanbankingnews.comCumberland Pharmaceuticals Updates Ifetroban DMD Trial TimelineAugust 28, 2026 | tipranks.comWATCH THIS BEFORE SEPTEMBER 25TH!!James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has noticed it. Altucher believes the filing could matter to as many as 1,806,000 Americans in the years ahead. He explains why Musk buried it and what it could mean, free of charge.September 22 at 1:00 AM | Paradigm Press (Ad)Cumberland Pharmaceuticals: Pivot Into Drug Development Creates Risk, OpportunityAugust 13, 2026 | seekingalpha.comCumberland Pharmaceuticals Inc. (CPIX) Q2 2026 Earnings Call TranscriptAugust 4, 2026 | seekingalpha.comCUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTSAugust 4, 2026 | prnewswire.comCUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTSJuly 28, 2026 | prnewswire.comCumberland Pharmaceuticals Announces Special Dividend, Share BuybackJuly 13, 2026 | tipranks.comSee More Headlines CPIX Stock Analysis - Frequently Asked Questions How have CPIX shares performed this year? Cumberland Pharmaceuticals' stock was trading at $3.98 at the beginning of the year. Since then, CPIX shares have increased by 98.0% and is now trading at $7.8820. How were Cumberland Pharmaceuticals' earnings last quarter? Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) released its earnings results on Tuesday, August, 4th. The specialty pharmaceutical company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $0.07. The specialty pharmaceutical company earned $0.17 million during the quarter, compared to analysts' expectations of $8.50 million. Cumberland Pharmaceuticals had a negative net margin of 34.40% and a negative trailing twelve-month return on equity of 28.81%. Read the conference call transcript. Who are Cumberland Pharmaceuticals' major shareholders? Top institutional investors of Cumberland Pharmaceuticals include BlackRock Inc. (0.42%) and Bank of New York Mellon Corp (0.39%). View institutional ownership trends. How do I buy shares of Cumberland Pharmaceuticals? Shares of CPIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cumberland Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cumberland Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), ExxonMobil (XOM), Netflix (NFLX) and Intel (INTC). Company Calendar Record date for 7/31 Dividend7/23/2026Dividend Payable7/31/2026Last Earnings8/04/2026Today9/22/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 CPIX's financial health is in the Green zone, according to TradeSmith. CPIX has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CPIX CIK1087294 Webwww.cumberlandpharma.com Phone(615) 255-0068Fax615-255-0094Employees93Year Founded1999Profitability EPS (Trailing Twelve Months)($0.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.84 million Net Margins-34.40% Pretax Margin-23.38% Return on Equity-28.81% Return on Assets-9.25% Debt Debt-to-Equity RatioN/A Current Ratio0.96 Quick Ratio0.96 Sales & Book Value Annual Sales$44.52 million Price / Sales2.65 Cash Flow$0.39 per share Price / Cash Flow19.96 Book Value$1.64 per share Price / Book4.81Miscellaneous Outstanding Shares14,980,000Free Float8,680,000Market Cap$118.07 million OptionableOptionable Beta0.13 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:CPIX) was last updated on 9/22/2026 by MarketBeat.com Staff. From Our PartnersChina's dominance in rare earth processing sparks new defense rulesOn January 1, 2027, new Pentagon rules tighten sourcing restrictions on critical minerals tied to foreign adve...The Tomorrow Investor | Sponsored$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredThe AI Infrastructure Rush Is ON — Watch VDTAVertical Data Inc. (OTCQB: VDTA) is targeting the infrastructure layer beneath the AI boom, from GPU hardware ...Trading Wire | SponsoredInside Nevada's 60 Million Ounce Gold CorridorBarrick Mining has spent decades building one of the world's great gold districts in Nevada, anchored by Fourm...Wall Street Logic | SponsoredElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredPass by August 7… or wait until 2027?On August 14, federal regulators cleared a national trust bank tied to the Trump family's crypto venture. W...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cumberland Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cumberland Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
